Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
16.68
+0.65 (4.05%)
At close: Jun 26, 2026, 4:00 PM EDT
16.61
-0.07 (-0.42%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Intellia Therapeutics stock have an average target of 21.06, with a low estimate of 8.00 and a high estimate of 49. The average target predicts an increase of 26.26% from the current stock price of 16.68.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 11 | 13 | 13 | 11 | 11 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 11 | 11 | 9 | 9 | 9 | 8 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 25 | 25 | 25 | 25 | 23 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $49 | Buy | Maintains | $49 | +193.76% | Jun 16, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains $19 | Hold | Maintains | $19 | +13.91% | Jun 16, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Maintains $9 | Sell | Maintains | $9 | -46.04% | Jun 15, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Hold Maintains $12 | Hold | Maintains | $12 | -28.06% | Jun 15, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 15, 2026 |
Financial Forecast
Revenue This Year
59.97M
from 67.67M
Decreased by -11.38%
Revenue Next Year
265.93M
from 59.97M
Increased by 343.42%
EPS This Year
-3.17
from -3.81
EPS Next Year
-1.80
from -3.17
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 100.0M | 3.0B | |
| Avg | 60.0M | 265.9M | |
| Low | 15.0M | 3.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.8% | 4,919.7% | |
| Avg | -11.4% | 343.4% | |
| Low | -77.8% | -93.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.76 | 12.95 | |
| Avg | -3.17 | -1.80 | |
| Low | -3.75 | -4.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.